1 / 20

MBBS Cancer Biology Module 2006

MBBS Cancer Biology Module 2006. Tumour Vasculature and Therapeutic Strategies Barbara Pedley. TUMOUR ANGIOGENESIS. What is tumour angiogenesis? Why is it important? Why is it a good target for therapy?

samira
Télécharger la présentation

MBBS Cancer Biology Module 2006

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MBBS Cancer Biology Module 2006 Tumour Vasculature and Therapeutic Strategies Barbara Pedley

  2. TUMOUR ANGIOGENESIS • What is tumour angiogenesis? • Why is it important? • Why is it a good target for therapy? • What examples are there of cancer therapies that selectively target the vasculature?

  3. Tumour Angiogenesis • Formation of new vessels from pre-existing vasculature • Required for tumour growth (>1mm3) and metastasis Cell Differentiation Cell Migration tumour Angiogenic Stimulus Cell Division BM & ECM Breakdown

  4. Angiogenic Switch Initiated by switch in balance from anti- to pro-angiogenic factors

  5. Differences between tumour and normal vessels • High endothelial cell proliferation rate • (3-13 v 47-2000 day) • Distorted and chaotic architecture, with • sluggish blood flow, shunts and dead ends • Leaky vessels • Frequently results in regions of hypoxia

  6. Normal v tumour vessels normal tumour Well Oxygenated

  7. BUT: Tumour Vessel Abnormalities are Targetable • Advantages of Vessel v Tumour Cell Targeting • Rapidly dividing • Accessibility • 1 capillary supports many tumour cells • No drug resistance • Applicable to all solid tumours Tumour vessels

  8. TUMOUR BLOOD VESSELS: A TARGET FOR NOVEL THERAPEUTICS I. Endogenous inhibitors II. Small molecule inhibitors & antibodies III. Antivascular drugs All in clinical trials http//cancertrials.nci.nih.gov/news/angio/table.html Kerbel R & Folkman J. Clinical translation of angiogenesis inhibitors. Nature Reviews 2: 727-739, 2002. Falm E. Angiogenic inhibitors in clinical development. BJC 90: 1-7, 2004. Neri D & Bicknell R (2005). Tumour vascular targeting. Nature Reviews/ Cancer 5: 536-446.

  9. I. Endogenous inhibitors eg angiostatin Saline Angiostatin Effect of angiostatin on corneal vessel proliferation

  10. II. Small molecule inhibitors & antibodies • Inhibitors of matrix metalloproteinases • block ECM breakdown • Anti-integrin antibodieseg Vitaxin • block endothelial cell adhesion & survival • Anti-VEGF antibodies eg Avastin • blocks growth factor function & signalling The first anti-angiogenesis strategy to be licenced by the FDA to treat human cancer (2004)

  11. VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) • Expressed at high levels by many tumours • Reacts with receptors on vascular endothelium • Functions essential for tumour growth: • promotes angiogenesis • promotes vascular permeability • Clinical importance • high VEGF levels in tumour and plasma frequently • correlate with poor prognosis

  12. Bevacizumab (AvastinTM) - Survival IFL: bolus 5-FU 500 mg/m2 leucovorin 20 mg/m2 irinotecan 125 mg/m2 Expensive! Gerber & Ferrara, Cancer Res 65: 671-680, 2005

  13. V N 24 h post drug • III Antivascular Drugs eg.Combretastatin • tubulin binding agent/colchicine binding site • targets angiogenic and established tumour vessels • inhibits tumour blood flow • destroys all but the tumour rim V V Untreated

  14. Effect of colchicine therapy: 1945

  15. RADIOIMMUNOTHERAPY CT scans showing response Radionuclide 131I Antibody before Bystander effect Antigen eg CEA DNA strand breaks Cell death after Tumour cell

  16. Basis of Combined Therapies V N Combretastatin 24h Antibody Blood vessel distribution Therapy: RIT + CA4-P

  17. A Phase I/II Trial of Radioimmunotherapy with 131I-A5B7 anti-CEA Antibody in Combination with CA4-P for Advanced Gastrointestinal CarcinomaSTUDY PH1-092

  18. Summary of Tumour Vessels Tumour v normal blood vessels: • High endothelial cell proliferation rate • Abnormal morphology, biochemistry and physiology • Development of hypoxia leads to: • increased angiogenesis and tumour growth • tumour resistance to conventional therapies • altered gene expression • increased metastatic potential • However...…..

  19. Summary of Antivascular Therapy • The abnormal vasculature of solid tumours provides exciting new targets for therapy • Low drug resistance v tumour cells • Low toxicity • Long-term dosing frequently required • Combined therapies (eg anti-vascular + anti-tumour cell) will frequently be required to eradicate tumours

More Related